Pausing methotrexate improves immunogenicity of COVID-

19 vaccination in patients with rheumatic diseases

Arumahandi de Silva AN¹⁺, Frommert LM¹⁺, Albach FN¹, Klotsche J², Scholz V¹, Jeworowski LM³,

Schwarz T³, ten Hagen A¹, Zernicke J¹, Corman VM^{3,4}, Drosten C³, Burmester GR¹⁺, Biesen R¹⁺

¹ Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin

Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin,

Berlin, Germany

² German Rheumatism Research Center Berlin – a Leibniz Institute (DRFZ), Berlin, Germany

³ Institute of Virology, Charité - Universitätsmedizin Berlin, Freie Universität Berlin and

Humboldt-Universität zu Berlin, Berlin, Germany and German Centre for Infection Research

(DZIF), Associated Partner Site, Berlin, Germany

⁴ Labor Berlin, Charité - Vivantes GmbH, Berlin, Germany

† contributed equally

Keywords: rheumatic diseases, methotrexate, SARS-CoV-2, vaccination, antibody response

Address correspondence and reprint request:

Dr. med. Robert Biesen

Department of Rheumatology and Clinical Immunology

Charité University Hospital

Charitéplatz 1

D-10117 Berlin – Germany

E-mail: Robert.Biesen@charite.de

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

ABSTRACT

Objective: To study the effect of methotrexate (MTX) and its discontinuation on the humoral

immune response after COVID-19 vaccination in patients with autoimmune rheumatic diseases

(AIRD).

Methods: Neutralising SARS-CoV-2 antibodies were measured after second vaccination in 64

rheumatic patients on methotrexate therapy, 31 of whom temporarily paused medication

without a fixed regimen. The control group consisted of 21 AIRD patients without

immunosuppressive medication.

Results: MTX patients showed a significantly lower median antibody response compared to

AIRD patients without immunosuppressive therapy (p< 0.001). Young age (<60 years) and

MTX-hold after vaccination were found to be the main factors influencing antibody response

after vaccination, while BMI or MTX dose demonstrated no effect. For patients taking MTX, age

correlated negatively with immune response (r=-0.49; p<0.001) and all patients with antibody

levels (14 %) below the cut-off were older than 60 years. Patients who held MTX during at least

one vaccination showed significantly higher median neutralising antibody levels after second

vaccination, compared to patients who continued MTX therapy during both vaccinations (68.82

%, 92.73 %, p=<0.001). This effect was particularly pronounced in patients older than 60 years

(p=0.0016). The impact of the time period after vaccination was greater than of the time before

vaccination with the critical cut-off being 10 days.

Conclusion: MTX reduces the immunogenicity of SARS-CoV-2 vaccination in an age-

dependent manner. Our data further suggest that holding MTX for at least 10 days after

vaccination significantly improves the antibody response in patients over 60 years of age.

INTRODUCTION

Until November 2021, SARS-CoV-2 had infected at least 250 million people worldwide and

caused about 5 million deaths in a 23-month period ¹. At the same time, enormous knowledge

about SARS-CoV-2 and the related disease COVID-19 have been generated and the

possibilities for prevention, diagnostics and treatments have improved remarkably.

Methotrexate (MTX) has been used for decades to treat a wide variety of immune-mediated

diseases in oncology, rheumatology, dermatology, gastroenterology, and neurology. Following

prednisolone, MTX is the most prescribed anti-inflammatory drug worldwide with 1 million

MTX patients in the US alone ².

Various immunosuppressants reduce the immune response after COVID-19 vaccination and

40-44 % of hospitalised breakthrough infections happen to immunocompromised patients ³⁴.

Recently, MTX has also shown to reduce serological response after COVID-19 vaccination in

three cohorts with a total of 60 patients ^{5 6}. The discontinuation of immunosuppressive

medication can improve the vaccination response as recently shown for mycophenolate ⁷.

A reduced vaccination response under MTX was first described in 2016 for influenza vaccination

8. Follow-up data showed the increase in humoral immune response when pausing MTX two

weeks before and after vaccination or only two weeks after vaccination ⁹ ¹⁰. The time after and

not before vaccination was decisive ¹¹. Therefore, all current recommendations ¹² for COVID-19

vaccinations under MTX therapy are based on experience with influenza vaccines, not

considering mRNA-based technology used for COVID-19 vaccinations.

To understand the efficiency of MTX discontinuation during COVID-19 vaccination we analysed

SARS-CoV-2-spike specific neutralising antibodies from patients receiving MTX and either

continued therapy during both vaccinations (n=33) or a changed MTX schedule resulting in an

intake gap longer than 7 days (n=31).

METHODS

Study design and participants

This report depicts results of the VACCIMMUN Study, which is a retrospective cohort study among patients with autoimmune rheumatic diseases (AIRD) at Charité Medical Clinic for Rheumatology and Clinical Immunology. Clinical characterisation and blood sampling took place between June and September 2021. In addition, stored blood samples collected in April and May 2021 were used. Participants had to meet the following inclusion criteria: age 18 years or older, AIRD diagnosis and vaccination with a COVID-19 vaccine authorised for use in Germany. For this analysis, AIRD patients under MTX therapy were considered, receiving either only MTX or MTX combined with low dose prednisolone (defined as \leq 5 mg/d), TNF α -Inhibitors, hydroxychloroguine, leflunomide, IL-17 or IL-12/23 inhibitors, since these immunosuppressive comedications are not known to have a remarkable impact on the immune response during vaccination ¹³. Additionally, AIRD patients who were vaccinated under no immunosuppressive therapy served as controls. Information regarding medical history, including COVID-19 vaccination status and immunosuppressive therapy were provided directly by patients or retrieved from medical records. Patients who reported to have changed their MTX-intake schedule resulting in an MTX-interval longer than 7 days during first or second vaccination were compared to patients who continued MTX therapy throughout both vaccinations. This study was ethically approved by the Regional Office for Health and Social Affairs Berlin, Germany (21/0098-IV E 13). All patients provided written informed consent.

Laboratory analyses

Antibody response was measured predominantly about two weeks after the second dose of vaccination with maximum range from 11 to 112 days (Median 20, IQR 15, 47). Neutralising antibody levels were assessed using a surrogate virus neutralisation test (cPass Neutralisation, Medac GmbH, Wedel, Germany)¹⁴. Following the manufacturer's protocol, patients who reached inhibition rates greater than or equal to 30 % were considered to have demonstrated a SARS-CoV-2 specific humoral response and are further defined as responders, while patients with inhibition rates <30 % are defined as non-responders. Additionally, IgG antibodies against nucleocapsid, receptor binding domain (RBD), full spike and the S1 domain of the spike protein were tested using SeraSpot® Anti-SARS-CoV-2 IgG microarray-based immunoassay (Seramun

Diagnostica GmbH, Heidesee, Germany) and served here for further validation purposes. Hence, all calculations were additionally performed using anti-RBD-IgG levels and can be found in the supplements. The threshold for reactivity for anti-SARS-CoV-2 IgG levels was set at >1.00 Signal/Cut-off (S/CO) in accordance with manufacturer's protocol.

Statistical analysis

Descriptive statistics included median with interquartile range and absolute and relative frequencies. Fisher's exact test and Chi² test were applied for categorical data and the Mann-Whitney U test for continuously distributed variables to perform hypotheses tests for group differences, as appropriate. The likelihood of being a responder was modelled by a multivariable logistic regression model including the covariates age, body mass index (BMI), gender, MTX monotherapy and MTX-hold. These covariates were selected based on the theoretical assumption that they could affect vaccination success. The association between timing and duration of MTX-hold at the two vaccinations and neutralisation results were estimated by linear regression analyses (anti-RBD-IgG concentrations or neutralizing antibody levels by neutralisation result) and logistic regression analyses (anti-RBD-IgG concentration > 1 S/CO or neutralization capacity ≥30%)adequate neutralisation result) adjusted for duration between blood sampling and second vaccination and considering the clustering of the two vaccinations within a patient. The standardized beta coefficient was calculated for linear regression analyses to compare the strengths of association between parameters. The strength of association according to the standardized beta can be categorized into small (<0.1), medium (0.1 to 0.3), and large (>0.3) for continuously distributed variables and small (<0.3), medium (0.3 to 0.8), and large (>0.8) for categorical variables. The area under curve was calculated after fitting a logistic regression model to provide a measure of strengths of association for dichotomous outcomes. The Youden index was used to estimate thresholds for age and time of MTX break before and after vaccination from receiver-operating characteristics. Statistical analyses were performed using Graphpad Prism 9.2.0 and STATA 12.1.

Patient and public involvement

This study aimed to provide evidence for future recommendations due to questions asked regarding MTX intake by patients and physicians. However, patients and the public were not directly involved in process of designing.

RESULTS

Patient characteristics

Of 73 eligible patients receiving MTX, nine were excluded due to immunosuppressive comedication, irregular medication regimens and unclassifiable MTX-hold. The final cohort consisted of 64 AIRD patients taking MTX (median age 63.0 years, 70.3 % women) and 21 rheumatic patients who did not receive any kind of immunosuppressive therapy as a control group (median age 62, 90.5 % women). Detailed clinical characterisation is given in supplementary table 1. There were no significant differences between MTX therapy and the no-therapy group regarding age, BMI, distribution of sex, vaccination regimes, time between

Of 64 MTX patients, 31 patients reported to have held MTX for at least one vaccination (MTX-hold) while 33 patients had continued their MTX therapy without any interruption (MTX continued, table 2). Blood sampling occurred slightly earlier in the MTX-hold group than in the MTX continued group. There were no other significant differences between these two groups regarding age, BMI, distribution of sex, vaccination regimes, diagnoses and immunosuppressive comedications.

second vaccination and antibody measurements and comedications.

MTX reduces vaccination response

AIRD patients without immunosuppressive therapy showed a significantly higher neutralising capacity (median 95.9 %, IQR: 93.0, 96.6) than AIRD patients taking MTX (median= 82.5 %, IQR: 55.5, 95.6, p < 0.001, figure 1, supplementary figure 1 for anti-RBD-IgG). None of the patients without immunosuppressive therapy were classified as non-responders (defined by neutralisation activity < 30 %), compared to 14.1 % (n=9) among MTX patients. Taking patients without immunosuppressive therapy in our cohort as a reference group for a typical antibody response after vaccination, the threshold for a not-altered inhibition rate could be set at 87.64 % (AUC 0.75, Youden index 49.9). Accordingly, 38 of 64 MTX patients (59.4 %) demonstrated a lower antibody response after two vaccinations compared to an untreated group of AIRD patients.

Factors influencing antibody response in MTX patients

To identify factors influencing the antibody response under MTX we compared COVID-19vaccination responders (n=55, 85.9 %) and non-responders (n=9, 14.1 %) defined by neutralisation activity. Both groups were similar in BMI, vaccine type, MTX application form, additional prednisolone intake, time of blood draw and immunosuppressive comedication (table 1). Dosage of MTX was not significantly associated with vaccination success (Spearman rank test, r=-0.02, p value=0.867). However, a higher neutralization capacity was significantly associated with young age, MTX-hold and female gender in univariate analysis (table 1) and multivariable analysis (table 3). If classification into responders and non-responders was based on anti-RBD-IgG results, 13 patients fall into the non-responder group. While the effect of age and MTX-hold were still significant using anti-RBD-IgG levels, this was not the case for gender (supplementary table 2). Thus, we only analysed the effect of age and MTX-hold in more detail.

Effect of MTX-hold and age

Patients who had changed their MTX intake schedule for at least one vaccination showed a significantly higher antibody response than patients who continued their MTX intake (p=0.003, figure 2A, supplementary figure 2A for anti-RBD-IgG). Median neutralisation was 68.8 % for patients who continued their therapy and 92.7 % for patients who held MTX (table 2). There was only one non-responder (3.2 %) in the MTX-hold group, while there were eight non-responders (24.2 %) in the MTX continued group.

Vaccination response correlated significantly with age (Spearman rank test, -0.49, p<0.001, figure 3, supplementary figure 3 for anti-RBD-IgG). No patient younger than 60 years was classified a non-responder which is why we further distinguished the MTX hold and continue groups into patients older and younger than 60 years of age (figure 2B, supplementary figure 2B for anti-RBD-IgG). Considering only patients who continued their MTX intake, patients \geq 60 years of age (median 55.5 %) had a 32.1 percentage points lower median inhibition rate than patients < 60 years (median 87.6 %). Vice versa, neutralisation levels were 31.8 percentage points higher in patients older than 60 years who held MTX (median 87.4 %) compared to those who continued MTX (median 55.5 %). In contrast, when regarding patients under 60 years there were no significant differences in neutralisation rates between patients who held or continued MTX therapy.

Effect of timing and duration of MTX-hold

Due to the observational design of this study, patients were not instructed to hold MTX in a certain pattern, which resulted in a wide distribution of MTX intake regimens.

In the following we considered all 64 patients and analysed the MTX-interval at the time of vaccination, which was defined by the time between last MTX intake and vaccination (time before vaccination = T_{BV}) and the time between vaccination and re-intake of MTX (time after vaccination = T_{AV} , figure 4). One patient could not recall on which day MTX was taken and was therefore not considered for calculations of T_{BV} and T_{AV} . We found that the duration of the MTX-interval (T_{BV} + T_{AV}) significantly correlates with neutralising capacity (Spearman rank test, r = 0.47, p < 0.001). We further analysed which of these time periods is most likely to determine antibody response. By using linear regression analysis, we found T_{AV} to be highly significant for adequate neutralisation rate and anti-RBD-IgG concentration in the elderly, but not for younger patients (table 4). Here, ten days between vaccination and MTX re-intake (T_{AV}) were determined as the critical cut-off based on the Youden index from receiver operating characteristic curve. T_{BV} was only significant when regarding neutralisation capacity (table 4). In addition, the standardized beta value was higher for T_{AV} (beta_{st} 0.40) than for T_{BV} (beta_{st} 0.07).

DISCUSSION

Our study emphasizes a severely reduced COVID-19 vaccination response in elderly MTX patients, demonstrates the benefit of MTX-hold and delivers first evidence for possible recommendations for further COVID-19 vaccinations.

Using neutralising capacity and the manufacturer's cut-off, we found a slightly higher rate of vaccination responders among patients taking MTX (85.9 %) than previously reported (47 – 72 %) ^{5 6}. This might be due to the inclusion of patients who held MTX during vaccinations in our study. Using ROC analysis and an untreated control group, we found determined an adapted cut-off value and found adequate immune response in only 40.6 % of MTX patients. Hence, by regarding 64 MTX patients and a control group (n = 21) we confirmed the observations from previous studies that the antibody response is reduced under MTX therapy.

We determined young age, MTX-hold and female gender as the main factors influencing antibody response after vaccination. The negative influence of age on vaccination response was already known 15 16, however, the consideration of age was not yet differentiated in previous studies investigating immune response under MTX therapy. Our data allows the assumption that continuous MTX intake and old age are potentiating negative influences on humoral immune response after COVID-19 vaccination.

Patients who held MTX for at least one vaccination had a significantly higher immune response than those who continued MTX, which has not yet been described for COVID-19 vaccination. Nevertheless, our findings are in line with studies by Park et al. investigating the effect of MTXhold on the immune response to influenza vaccination ^{9 17}. More detailed analysis showed that time after vaccination is crucial, which was also described by Park et al. who recommended a MTX discontinuation of two weeks after influenza vaccination ^{10 11}. Also, current guidelines by the American College of Rheumatology as well as the German Society for Rheumatology recommend holding MTX one to two weeks after COVID-19 vaccination ^{12 13}. In our study, we found a minimum time of 10 days after vaccination to be critical for immune response in patients ≥ 60 years. The time before vaccination was only significant when regarding neutralisation capacity and could not be validated in anti-RBD-lgG analysis, also the low standardized beta value (betast 0.07) indicates a negligible effect of T_{BV}. Additionally, the

positive effect of MTX-hold was only statistically significant for patients 60 years or older. An effect also in younger patients might be observed in a larger cohort.

We validated all our neutralisation test results with an additional test system measuring anti-RBD-IgG levels. The latter defined four more patients as non-responders compared to the neutralisation test. This small number of conflicting test results is to be expected when using different test systems, especially for systems that do or do not distinguish between Ig subtypes and did not have an impact when validating our calculations. However, the uneven distribution of gender, among patients who had conflicting test results, caused our analyses to suggest a significant influence of gender on the neutralisation result may be due a statistical artifact and the effect of gender should be interpreted with caution and the effect of gender should be revised in an external larger cohort.

Limitations of our study were small case numbers and the retrospective design, which is why our findings should be validated in a randomized controlled trial in the future. Also, T-cellresponse were not part of our study design, however, according to current studies, it can be assumed that measuring antibody levels is an adequate mean to determine vaccine immunogenicity ¹⁸. In addition, we used multivariable statistical models analyses to additionally adjust for the potential confounders MTX monotherapy and MTX dose. A strength of our study was that we validated all our neutralisation test results with an additional test system measuring anti-RBD-lgG. We did not assess the safety of pausing MTX in our cohort, but current data do not indicate a significantly higher flare occurrence or disease activity in association with MTX discontinuation of two weeks ¹⁹.

In conclusion, we present real-world data that is of clinical relevance regarding upcoming booster vaccination campaigns initiated by several countries. We determined age and MTXhold as the main factors influencing antibody response during SARS-CoV-2 vaccinations and both aspects should be regarded when discussing MTX regimens. Our data suggest that, if possible, patients older than 60 years of age should hold MTX for at least 10 days after receiving a COVID-19-vaccination.

Key messages

What is already known about this subject?

- Patients receiving methotrexate (MTX) have a reduced immune response after COVID-19 vaccination and holding MTX has shown to increase the immunogenicity after influenza vaccination.
- Yet, no previous studies have analysed the effect of MTX-hold for COVID-19 vaccination.

What does this study add?

- This study identified old age (≥ 60 years) and MTX continuation as critical factors for an inadequate antibody response.
- We found a minimum of 10 days between vaccination and re-intake of MTX as the critical threshold to increase immunogenicity for patients ≥ 60 years of age.

How might this impact on clinical practise or future developments?

 In regard of upcoming booster vaccination campaigns, our data suggest that especially older MTX patients should hold MTX for at least 10 days after receiving a COVID-19 vaccination, if possible. perpetuity.
It is made available under a CC-BY-ND 4.0 International license .

Acknowledgements: We would like to thank Tanja Braun and Vera Höhne-Zimmer for their

support in obtaining the ethics vote and for their organisational support.

Contributors: All authors contributed to the acquisition, analysis or interpretation of data and

critical revision of the manuscript for important intellectual content. RB had full access to all

the data in the study and takes responsibility for the integrity of the data and the accuracy of

the data analysis. FA, JZ, GB, RB were involved in the study design. Sample collection was done

by AS, LF, FA, VS, AH, JZ. Experiments and data analysis were performed by AS, LF, FA, JK, LJ,

TS, JZ, VC, CD, GB and RB. AS, LF, FA and RB were responsible for tables and figures. Data

interpretation was done by all authors. Statistical analyses were done by AS, LF, FA, JK and RB.

Writing of the manuscript were performed by AS, LF, FA, JK, GB and RB. All authors were

involved in critical proof reading of the manuscript.

Competing interests: VC is named together with Euroimmun GmbH on a patent application

filed recently regarding the diagnostic of SARS-CoV-2 by antibody testing.

Patient consent: All patients provided written informed consent.

Funding: This study did not receive any funding.

Ethics approval: The Berlin State Office for Health and Social Affairs (Turmstrasse 21, 10559

Berlin, Germany) has approved this study under file number 21/0098-IV E 13.

Data sharing statement: Data are available on reasonable request. All data relevant to the

study are included in the article or uploaded as online supplemental information.

REFERENCES

- 1. Ritchie H, Mathieu E, Rodés-Guirao L, et al. Coronavirus Pandemic (COVID-19): Our World in Data; 2020 [Available from: https://ourworldindata.org/coronavirus-data accessed 14.11.2021 2021.
- 2. Kane S. Methotrexate 2021 [updated September 15, 2021. Available from: https://clincalc.com/DrugStats/Drugs/Methotrexate accessed November 14, 2021.
- Brosh-Nissimov T, Orenbuch-Harroch E, Chowers M, et al. BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel. *Clin Microbiol Infect* 2021;27(11):1652-57. doi: 10.1016/j.cmi.2021.06.036 [published Online First: 2021/07/11]
- Tenforde MW, Patel MM, Ginde AA, et al. Effectiveness of SARS-CoV-2 mRNA Vaccines for Preventing Covid-19 Hospitalizations in the United States. *Clin Infect Dis* 2021 doi: 10.1093/cid/ciab687 [published Online First: 2021/08/07]
- 5. Mahil SK, Bechman K, Raharja A, et al. The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study. *The Lancet Rheumatology* 2021;3(9):e627-e37.
- 6. Haberman RH, Herati R, Simon D, et al. Methotrexate hampers immunogenicity to

 BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease.

 Annals of the Rheumatic Diseases 2021
- 7. Connolly CM, Chiang TP-Y, Boyarsky BJ, et al. Temporary hold of mycophenolate augments humoral response to SARS-CoV-2 vaccination in patients with rheumatic and musculoskeletal diseases: a case series. *Annals of the Rheumatic Diseases* 2021
- 8. Winthrop KL, Silverfield J, Racewicz A, et al. The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis. *Annals of the Rheumatic Diseases* 2016;75(4):687-95. doi: 10.1136/annrheumdis-2014-207191
- 9. Park JK, Lee YJ, Shin K, et al. Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial. *Ann Rheum Dis* 2018;77(6):898-904. doi: 10.1136/annrheumdis-2018-213222 [published Online First: 2018/03/25]
- 10. Park JK, Lee MA, Lee EY, et al. Effect of methotrexate discontinuation on efficacy of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised

- clinical trial. *Annals of the Rheumatic Diseases* 2017;76(9):1559-65. doi: 10.1136/annrheumdis-2017-211128
- 11. Park JK, Choi Y, Winthrop KL, et al. Optimal time between the last methotrexate administration and seasonal influenza vaccination in rheumatoid arthritis: post hoc analysis of a randomised clinical trial. *Annals of the rheumatic diseases* 2019;78(9):1283-84.
- 12. Curtis JR, Johnson SR, Anthony DD, et al. American College of rheumatology guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: version 4. *Arthritis & Rheumatology* 2021:5.
- 13. Specker C, Aries P, Braun J, et al. Aktualisierte Handlungsempfehlungen der Deutschen Gesellschaft für Rheumatologie für die Betreuung von Patienten mit entzündlichrheumatischen Erkrankungen im Rahmen der SARS-CoV-2/COVID-19-Pandemie einschließlich Empfehlungen zur COVID-19-Impfung. Zeitschrift für Rheumatologie 2021:1-17.
- 14. Tan CW, Chia WN, Qin X, et al. A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2–spike protein–protein interaction. *Nature biotechnology* 2020;38(9):1073-78.
- 15. Schwarz T, Tober-Lau P, Hillus D, et al. Delayed antibody and T-cell response to BNT162b2 vaccination in the elderly, Germany. *Emerging Infectious Diseases* 2021;27(8):2174.
- 16. Müller L, Andrée M, Moskorz W, et al. Age-dependent immune response to the Biontech/Pfizer BNT162b2 COVID-19 vaccination. *medRxiv*: the preprint server for health sciences 2021
- 17. Park JK, Lee MA, Lee EY, et al. Effect of methotrexate discontinuation on efficacy of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial. *Ann Rheum Dis* 2017;76(9):1559-65. doi: 10.1136/annrheumdis-2017-211128 [published Online First: 2017/05/05]
- 18. Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. *Nature medicine* 2021:1-7.
- 19. Park JK, Kim MJ, Choi Y, et al. Effect of short-term methotrexate discontinuation on rheumatoid arthritis disease activity: post-hoc analysis of two randomized trials. *Clinical rheumatology* 2020;39(2):375-79.

Tables

Table 1: Comparison of vaccination responders and non-responders

	Responders* (n=55)	Non-Responders (n=9)	P value [†]
Age, median (IQR)	61 (52, 70)	72 (64, 76)	0.007
Female, n (%)	42 (76.4)	3 (33.3)	0.016
BMI, median (IQR)	24.8 (22.0, 28.3)	27.1 (24.3, 29.5)	0.287
Medication			0.844
MTX-Mono, n (%)	31 (56.4)	7 (77.8)	
MTX+Anti-TNFα, n (%) [‡]	16 (29.1)	2 (22.2)	
MTX+HCQ, n (%)	2 (3.6)	0	
MTX+Leflunomide, n (%)	3 (5.5)	0	
MTX+Anti-IL-17, n (%)§	2 (3.6)	0	
MTX+Anti-IL-12/23, n (%)**	1 (1.8)	0	
MTX dose [mg/week], median (IQR)	15.0 (10.0, 15.0)	15.0 (10.0, 17.5)	0.423
MTX oral application, n (%)	25 (45.5)	1 (11.1)	0.071
Additional prednisolone, n (%)	15 (27.3)	5 (55.6)	0.124
Prednisolone dose [mg/day], median (IQR)	2.5 (1.5, 3.0)	5.0 (2.0, 5.0)	0.230
Vaccination			0.609
BNT162b2, n (%)	39 (70.9)	8 (88.9)	
mRNA-1273, n (%)	7 (12.7)	1 (11.1)	
AZD1222, n (%)	7 (12.7)	0	
AZD1222 + BNT162b2, n (%)	2 (3.6)	0	
days from second vaccination, median (IQR)	19 (15, 42)	40 (17, 58)	0.156
MTX-hold, n (%)	30 (54.5)	1 (11.1)	0.027
for both vaccinations, n	23 (41.8)	1 (11.1)	
for only the 1st vaccination, n	2 (3.6)	0	
for only the 2nd vaccination, n	5 (9.0)	0	

MTX, methotrexate; HCQ, hydroxychloroquine.

^{*} Defined by neutralising capacity against SARS-CoV-2 ≥30 %

[†] P values were calculated using Fisher's exact test or Chi² test for categorical variables and Mann–Whitney U test for continuous variables.

[‡] Adalimumab, Certolizumab, Etanercept, Golimumab, Infliximab.

[§] Secukinumab.

^{**} Ustekinumab.

Table 2: Characteristics of MTX patients who held and continued MTX

	MTX continued (n=33)	MTX-hold (n=31)	MTX all (n=64)	P value*
Age, median (IQR)	65 (56, 73)	61 (54, 70)	63 (55, 71)	0.177
Female, n (%)	21 (63.6)	24 (77.4)	45 (70.3)	0.280
BMI, median (IQR)	26.4 (23.1, 29.2)	24.6 (22.0, 27.2)	25.0 (22,9, 28.4)	0.119
Rheumatic diagnosis				0.759
Rheumatoid arthritis, n (%)	21 (63.6)	23 (74.2)	44 (68.8)	
Psoriatic arthritis, n (%)	5 (15.2)	2 (6.5)	7 (10.9)	
Others, n (%) [†]	7 (21.2)	6 (19.4)	13 (20.3)	
Medication				0.498
MTX-Mono, n (%)	21 (63.6)	17 (54.8)	38 (59.4)	
MTX+Anti-TNFα, n (%)‡	9 (27.3)	9 (29.0)	18 (28.1)	
MTX+others, n (%)§	3 (9.1)	5 (16.1)	8 (12.5)	
Additional prednisolone, n (%)	12 (36.4)	8 (25.8)	20 (31.3)	0.425
Prednisolone dose [mg/d], median (IQR)	2.3 (1.3, 5)	2.5 (2.0, 2.9)	2.5 (2.0, 5.0)	1.0
MTX dose [mg/week], median (IQR)	15.0 (10.0, 15.0)	15.0 (10.0, 15.0)	15.0 (10.0, 15.0)	0.932
MTX oral application, n (%)	16 (48.5)	10 (32.3)	26 (40.6)	0.212
Vaccination				0.896
BNT162b2, n (%)	24 (72.7)	23 (74.2)	47 (73.4)	
mRNA-1273, n (%)	5 (15.2)	3 (9.7)	8 (12.5)	
AZD1222, n (%)	3 (9.1)	4 (12.9)	7 (10.9)	
AZD1222 + BNT162b2, n (%)	1 (3.0)	1 (3.2)	2 (3.1)	
Immune Response				
days from 2 nd vaccination, median (IQR)	24 (16, 55)	17 (14, 38)	20 (15, 47)	0.048
Anti-RBD-IgG [S/CO], median (IQR)	2.6 (0.4, 6.1)	6.7 (5.4, 8.1)	5.7 (1.5, 7.7)	0.002
Neutralising capacity [%], median (IQR)	68.8 (32.1, 88.4)	92.7 (76.4, 96.6)	82.5 (55.5, 95.6)	< 0.001
Responders, neutralisation capacity, n (%)**	25 (75.8)	30 (96.8)	55 (85.9)	0.027
Responders, anti-RBD-IgG response, n (%)	21 (63.6)	30 (96.8)	51 (79.7)	0.001
MTX-hold				
for both vaccinations, n (%)	NA	24 (77.4)		
for only the 1 st vaccination, n (%)	NA	2 (6.5)		
for only the 2 nd vaccination, n (%)	NA	5 (16.1)		
duration of MTX-hold for 1st vaccination [days], median (IQR)	NA	14.0 (10.0, 21.0)		
duration of MTX-hold for 2nd vaccination [days], median (IQR)	NA	14.0 (14.0, 21.0)		

^{**} P values were calculated using Fisher`s exact test or Chi² test for categorical variables and Mann–Whitney U test for continuous variables.

[†] For MTX continued: ANCA-associated vasculitis (n=1), Axial spondyloarthritis (n=1), Polymyalgia rheumatica (n=2), Systemic sclerosis (n=1), Myositis (n=1), Systemic lupus erythematosus (n=1). For MTX-hold: Axial spondyloarthritis (n=1), Polymyalgia rheumatica (n=1), Primary Sjogren's syndrome (n=1), Systemic sclerosis (n=2), Myositis (n=1).

[‡] Adalimumab, Certolizumab, Etanercept, Golimumab, Infliximab.

 $[\]S$ For MTX continued: hydroxychloroquine (n=1), secukinumab (IL-17-inhibitor, n=1), ustekinumab (IL-12/23-inhibitor, n=1). For $MTX-hold: hydroxychloroquine \ (n=1), leflunomide \ (n=3), secukinumab \ (IL-17-inhibitor, \ n=1).$

^{**} Defined as neutralising capacity against SARS-CoV-2 ≥30%. MTX, methotrexate.

Table 3: Univariate and multivariable analysis

	univariate analysis				multivariable analysis			
	RR	p value	95%CI	AUC	RR	p value	95%CI	
Outcome: Anti-RBD-IgG	Outcome: Anti-RBD-IgG concentration >1 S/CO							
Female	1.18	0.280	0.88 ; 1.58	0.60	1.22	0.150	0.93 ; 1.61	
Age in years¶	0.93	<0.001	0.89 ; 0.97	0.89	0.92	<0.001	0.89 ; 0.96	
BMI in kg/m²	0.98	0.353	0.95 ; 1.02	0.58	1.00	0.933	0.97 ; 1.03	
MTX monotherapy	1.04	0.750	0.83 ; 1.30	0.53	1.06	0.556	0.87 ; 1.29	
MTX dose in mg	0.99	0.688	0.97 ; 1.02	0.54				
MTX hold	1.39	0.006	1.10 ; 1.76	0.74	1.30	0.014	1.05 ; 1.60	
Outcome: neutralisation	ı capaci	ty ≥30%						
Female	1.36	0.055	0.99 ; 1.87	0.72	1.42	0.022	1.05 ; 1.91	
Age in years¶	0.96	0.008	0.92 ; 0.99	0.77	0.95	0.007	0.92 ; 0.99	
BMI in kg/m²	0.99	0.385	0.97 ; 1.01	0.61	1.00	0.802	0.97 ; 1.02	
MTX monotherapy	1.05	0.624	0.86 ; 1.28	0.54	1.11	0.236	0.93 ; 1.32	
MTX dose in mg	0.99	0.452	0.97 ; 1.01	0.58				
MTX hold	1.28	0.019	1.04 ; 1.57	0.72	1.18	0.039	1.01 ; 1.46	

AUC = Area under Curve; 95%CI = 95% confidence interval; RR = relative risk ¶ relative risk for increase by 5 years

Table 4: Linear regression analysis for the association of MTX-intake timing

	All patients		Patients ≥ 60 years		Patients < 60 years	
	beta _{st} *	p value	betast	p value	beta₅t	p value
neutralisation capacity						
T_BV	0.18	0.065	0.19	0.087	0.07	0.793
T_{AV}	0.28	0.007	0.32	0.011	0.11	0.541
T _{BV} ≥ 10 days	0.07	0.439	0.07	0.007	-0.15	0.605
T _{AV} ≥ 10 days	0.33	< 0.001	0.40	< 0.001	0.09	0.702
$T_{BV} + T_{AV}$	0.34	< 0.001	0.39	< 0.001	0.14	0.215
anti-RBD-IgG						
T_BV	0.09	0.366	0.14	0.254	-0.08	0.699
T_{AV}	0.37	< 0.001	0.40	0.001	0.27	0.200
T _{BV} ≥ 10 days	0.01	0.919	0.00	0.976	-0.15	0.461
T _{AV} ≥ 10 days	0.35	0.001	0.47	< 0.001	0.10	0.65
$T_{BV} + T_{AV}$	0.36	<0.001	0.42	<0.001	0.17	0.455

^{*} beta_{st}: standardized beta coefficient adjusted for duration between blood sampling and second vaccination. The strength of association can be categorized into small (<0.1), medium (0.1 to 0.3), and large (>0.3) for continuously distributed variables and small (<0.3), medium (0.3 to 0.8), and large (>0.8) for categorical variables.

T_{BV} (time before vaccination), time between last MTX-intake and vaccination.

T_{AV} (time after vaccination), time between vaccination and re-intake of MTX.

 $T_{BV}+T_{AV}$, MTX-interval at the time of vaccination.

Supplementary table 1: Characteristics of MTX-patients and control-group

	MTX-therapy (n=64)	No therapy (n=21)	All (n=85)	P value*
Age, median (IQR)	63 (55, 71)	62 (48, 73)	62 (52 ,71)	0.917
Female, n (%)	45 (70.3)	19 (90.5)	64 (75.3)	0.082
BMI, median (IQR)	25.0 (22,9, 28.4)	23.6 (21.0, 26.6)	24.8 (22.0, 28.0)	0.093
Rheumatic diagnosis				<0.001
Rheumatoid arthritis, n (%)	44 (68.6)	3 (14.3)	47 (55.3)	
Psoriatic arthritis, n (%)	7 (10.9)	2 (9.5)	9 (10.6)	
Systemic sclerosis	3 (4.7)	8 (38.1)	11 (12.9)	
Others, n (%) [†]	10 (15.6)	8 (38.1)	18 (21.2)	
Vaccination				0.542
BNT162b2, n (%)	47 (73.4)	16 (76.2)	63 (74.1)	
mRNA-1273, n (%)	8 (12.5)	2 (9.5)	10 (11.8)	
AZD1222, n (%)	7 (10.9)	1 (4.8)	8 (9.4)	
AZD1222 + mRNA, n (%) [‡]	2 (3.1)	2 (9.5)	4 (4.7)	
Immune response				
days from 2 nd vaccination, median (IQR)	20 (15, 47)	22 (15, 53)	21 (15, 48)	0.946
Anti-RBD-IgG [S/CO], median (IQR)	5.7 (1.5, 7.7)	6.8 (5.8, 8.6)	6.0 (2.6, 7.8)	0,018
Neutralising capacity [%], median (IQR)	82.5 (55.5, 95.6)	95.9 (93.0, 96.6)	88.1 (67.9, 96.1)	<0.001
Responders, n (%) [§]	55 (85.9)	21 (100)	76 (89.4)	0.104

^{*} P values were calculated using Fisher's exact test or Chi² test for categorical variables and Mann–Whitney U test for continuous variables.

[†] For MTX group: ANCA-associated vasculitis (n=1), Axial spondyloarthritis (n=2), Polymyalgia rheumatica (n=3), Primary Sjogren's syndrome (n=1), Myositis (n=2), Systemic lupus erythematosus (n=1).

For no therapy group: Axial spondyloarthritis (n=2), Polymyalgia rheumatica (n=1), Primary Sjogren's syndrome (n=2), Systemic lupus erythematosus (n=1), Familial Mediterranean fever (n=1), peripheral spondyloarthritis (n=1).

[‡] MTX group: AZD1222 + BNT162b2 (n=2). No-therapy-group: AZD1222 + BNT162b2 (n=1), AZD1222 + mRNA-1273 (n=1).

[§] Defined by neutralising capacity against SARS-CoV-2 ≥ 30 %. MTX, methotrexate.

Supplementary table 2: Comparison of vaccination Responders and Non-Responders (anti-RBD-IgG levels)

	Responders* (n=51)	Non-Responders (n=13)	P value⁺
Age, median (IQR)	61 (51, 69)	73 (66, 79)	<0.001
Female, n (%)	38 (74.5)	7 (53.8)	0.180
BMI, median (IQR)	25.0 (22.0, 28.3)	25.0 (23.8, 29.5)	0.420
Medication			0.799
MTX-Mono, n (%)	29 (56.9)	9 (69.2)	
MTX+Anti-TNFα, n (%) [‡]	14 (27.5)	4 (30.8)	
MTX+HCQ, n (%)	2 (3.9)	0	
MTX+Leflunomide, n (%)	3 (5.9)	0	
MTX+Anti-IL-17, n (%)§	2 (3.9)	0	
MTX+Anti-IL-12/23, n (%)**	1 (2.0)	0	
MTX dose [mg/week], median (IQR)	15.0 (10.0, 15.0)	15.0 (10.0, 15.0)	0.957
MTX oral application, n (%)	23 (45.1)	3 (23.1)	0.210
Additional prednisolone, n (%)	13 (25.5)	7 (53.8)	0.090
Prednisolone dose [mg/day], median (IQR)	2.5 (2.0, 4.0)	2.0 (1.0, 5.0)	0.811
Vaccination			0.336
BNT162b2, n (%)	35 (68.6)	12 (92.3)	
mRNA-1273, n (%)	7 (13.7)	1 (7.7)	
AZD1222, n (%)	7 (13.7)	0	
AZD1222 + BNT162b2, n (%)	2 (3.9)	0	
days from second vaccination, median (IQR)	18 (15, 42)	40 (17, 58)	0.074
MTX-hold, n (%)	30 (58.8)	1 (7.7)	0.001
for both vaccinations, n	23	1	/
for only the 1st vaccination, n	2	0	/
for only the 2nd vaccination, n	5	0	/

MTX, methotrexate; HCQ, hydroxychloroquine.

^{*} Defined by anti-SARS-CoV-2-RBD-IgG>1.00 S/CO.

[†] P values were calculated using Fisher's exact test or Chi² test for categorical variables and Mann–Whitney U test for continuous variables.

[‡] Adalimumab, Certolizumab, Etanercept, Golimumab, Infliximab.

[§] Secukinumab.

^{**} Ustekinumab.

Figures

Figure 1: Comparison of neutralising capacity in AIRD patients without

immunosuppression and with MTX therapy. Neutralising capacity measured using surrogate

virus neutralisation test after second vaccination in MTX-patients (n=64) represented by red dots

vs. AIRD patients who were under no immunosuppressive therapy during both vaccinations

(n=21) represented by green dots.

Figure 2: Comparison of AIRD patients who continued or held their MTX during the

COVID-19 vaccination. (A) Neutralising capacity measured using surrogate virus neutralisation

test compared between patients who held MTX during vaccination (n=33) and patients who

continued MTX-therapy (n=31). (B) Neutralising capacity differentiated by age groups <60 years

and ≥60 years. P values were calculated using the non-parametric Mann Whitney U test. Dotted

line marks the cut-off value following manufacturer's protocol (≥30 %). Yellow squares represent

patients who continued MTX-therapy, purple dots represent patients who held MTX for at least

one vaccination.

Figure 3: Correlation of Age and neutralising capacity measured using surrogate virus

neutralisation test. Purple dots represent patients who held MTX during vaccination (n=31),

yellow squares represent patients who continued MTX-therapy (n=33). Neutralising antibodies

were measured using a surrogate virus neutralisation test. Dotted lines mark the cut-off value

following manufacturer's protocol (≥30 %) and the cut-off age used for further analysis at 60

years. P value and correlation coefficient were calculated using the Spearman Rank test.

Figure 4: Visualization of analysed time intervals. Time between MTX-intakes and COVID-

19 vaccinations were assessed for each vaccination and added together to receive the total time

before vaccinations (TBV=TBV1+TBV2) and after vaccinations (TAV=TAV1+TAV2). The MTX-

interval was defined as the total durations between two MTX intakes at the time of vaccination

(TAV + TBV).

Supplementary figure 1: Comparison of anti-RBD-IgG-antibody levels in AIRD patients

without immunosuppression and with MTX therapy. Anti-RBD-IqG-antibody levels after

second vaccination in MTX-patients (n=64) represented by red dots vs. patients who were under

no immunosuppressive therapy during both vaccinations (n=21) represented by green dots.

perpetuity.

It is made available under a CC-BY-ND 4.0 International license .

Supplementary figure 2: Comparison of AIRD patients who continued or held their MTX during the COVID-19 vaccination. (A) Anti-RBD-IgG concentrations compared between patients who held MTX during vaccination (n=33) and patients who continued MTX-therapy (n=31). (B) Anti-RBD-IgG concentrations differentiated by age groups <60 years and \geq 60 years. P values were calculated using the non-parametric Mann Whitney U test. Dotted line marks the cut-off value following manufacturer's protocol (>1 S/CO). Yellow squares represent patients who continued MTX-therapy, purple dots represent patients who held MTX for at least one vaccination.

Supplementary figure 3: Correlation of Age and Anti-RBD-IgG-Antibody concentrations. Purple dots represent patients who held MTX during vaccination (n=31), yellow squares represent patients who continued MTX-therapy (n=33). Dotted lines mark the cut-off antibody concentration for adequate humoral immune response following manufacturer's protocol (>1 S/CO) and the cut-off age observed for this cohort at 60 years. P value and correlation coefficient were calculated using the Spearman Rank test.













